Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics, Inc. (RAPP) is a healthcare company (biotechnology) based in the United States. The share price is $24.06, down 3.06% on the day, which values the company at $1.43B. Price as of 17 Nov 2026, 17:26 UTC, from Yahoo Finance.

Key facts

Share price
$24.06−3.06% today
Market value
$1.43B
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Rapport Therapeutics, Inc. in more detail

RAPP trades at -6.1× next year's expected earnings, 71.3× sales.

In its favour: More cash than debt. Worth checking: Weak Piotroski score; Debt is growing faster than cash flow.

1 of the superinvestors tracked here hold RAPP, including Julian and Felix Baker (0.3% of the portfolio).

Superinvestors holding RAPP

1 of the investors tracked here report a position in their latest 13F filing.

Rapport Therapeutics, Inc. (RAPP): questions and answers

What is Rapport Therapeutics, Inc.'s market cap?

Rapport Therapeutics, Inc. is valued at $1.43B at a share price of $24.06.

Does RAPP pay a dividend?

Rapport Therapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own RAPP?

In their latest quarterly filings, Julian and Felix Baker (0.3% of the portfolio) hold RAPP. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Rapport Therapeutics, Inc. (RAPP) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/RAPP

Underlying data: Yahoo Finance; company filings with the SEC.